Zentalis Pharmaceuticals (ZNTL) Payables (2019 - 2026)

Zentalis Pharmaceuticals has reported Payables for 8 years, with the latest figure at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 5.03% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $7.4 million (down 5.03% YoY), and the FY2025 full-year result was $7.2 million, down 3.09% from the prior year.
• Payables for Q1 2026 stood at $7.4 million, up from $7.2 million in the prior quarter.
• The five-year high for Payables was $20.4 million in Q2 2024, with the low at $3.7 million in Q2 2025.
• Average Payables over 5 years is $10.6 million, with a median of $10.5 million recorded in 2024.
• Year-over-year, Payables soared 66.11% in 2024 and sank 81.81% in 2025.
• Tracing ZNTL's Payables over 5 years: stood at $11.2 million in 2022, then soared by 32.71% to $14.9 million in 2023, then slumped by 50.17% to $7.4 million in 2024, then retreated by 3.09% to $7.2 million in 2025, then increased by 2.36% to $7.4 million in 2026.
• The last three Payables figures came in at $7.4 million (Q1 2026), $7.2 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.

Peer Comparison